Co-Authors
This is a "connection" page, showing publications co-authored by Sushila R. Dalal and David T. Rubin.
Connection Strength
4.729
-
A Comparative Analysis of Clinical Symptoms and Modified Pouchitis Disease Activity Index Among Endoscopic Phenotypes of the J Pouch in Patients With Inflammatory Bowel Disease. Crohns Colitis 360. 2024 Jul; 6(3):otae045.
Score: 0.245
-
Endoscopic Normalization and Transition of J-Pouch Phenotypes Over Time in Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2024 Jun 25.
Score: 0.244
-
Real World Clinical Effectiveness and Safety of Ozanimod in the Treatment of Ulcerative Colitis: 1-Year Follow-Up from a Tertiary Center. Dig Dis Sci. 2024 Feb; 69(2):579-587.
Score: 0.235
-
Upadacitinib Is Effective and Safe in Both Ulcerative Colitis and Crohn's Disease: Prospective Real-World Experience. Clin Gastroenterol Hepatol. 2023 07; 21(7):1913-1923.e2.
Score: 0.223
-
Endo-histologic Normalization Is Achievable with Tofacitinib and Is Associated with Improved Clinical Outcomes. Dig Dis Sci. 2023 04; 68(4):1464-1472.
Score: 0.217
-
Outcomes of Ileoanal Pouch Anastomosis in Pediatric Ulcerative Colitis Are Worse in the Modern Era: A Time Trend Analysis Outcomes Following Ileal Pouch-Anal Anastomosis in Pediatric Ulcerative Colitis. Inflamm Bowel Dis. 2022 09 01; 28(9):1386-1394.
Score: 0.215
-
Ozanimod Maintenance Therapy After Cyclosporine Induction in Acute Severe Ulcerative Colitis. ACG Case Rep J. 2022 Jul; 9(7):e00832.
Score: 0.213
-
Histopathology of Colectomy Specimens Predicts Endoscopic Pouch Phenotype in Patients with Ulcerative Colitis. Dig Dis Sci. 2022 08; 67(8):4020-4031.
Score: 0.208
-
Factors associated with anti-tumor necrosis factor effectiveness to prevent postoperative recurrence in Crohn's disease. Intest Res. 2022 Jul; 20(3):303-312.
Score: 0.199
-
Endoscopic Phenotype of the J Pouch in Patients With Inflammatory Bowel Disease: A New Classification for Pouch Outcomes. Clin Gastroenterol Hepatol. 2022 02; 20(2):293-302.e9.
Score: 0.193
-
Efficacy and safety of induction therapy with calcineurin inhibitors followed by vedolizumab maintenance in 71 patients with severe steroid-refractory ulcerative colitis. Aliment Pharmacol Ther. 2020 03; 51(6):637-643.
Score: 0.178
-
Ciclosporin Therapy After Infliximab Failure in Hospitalized Patients With Acute Severe Colitis is Effective and Safe. J Crohns Colitis. 2019 Sep 19; 13(9):1105-1110.
Score: 0.175
-
Follow-Up of Patients With Ulcerative Colitis and Histological Normalization. Clin Gastroenterol Hepatol. 2020 04; 18(4):987-988.e1.
Score: 0.172
-
Ustekinumab Is Effective for the Treatment of Chronic Antibiotic-Refractory Pouchitis. Dig Dis Sci. 2019 12; 64(12):3596-3601.
Score: 0.172
-
Real-World Experience with Tofacitinib in IBD at a Tertiary Center. Dig Dis Sci. 2019 07; 64(7):1945-1951.
Score: 0.168
-
Correction to: Risk Factors for Clostridium difficile Isolation in Inflammatory Bowel Disease: A Prospective Study. Dig Dis Sci. 2018 10; 63(10):2815.
Score: 0.164
-
Risk Factors for Clostridium difficile Isolation in Inflammatory Bowel Disease: A Prospective Study. Dig Dis Sci. 2018 04; 63(4):1016-1024.
Score: 0.157
-
Early Transcriptomic Changes in the Ileal Pouch Provide Insight into the Molecular Pathogenesis of Pouchitis and Ulcerative Colitis. Inflamm Bowel Dis. 2017 03; 23(3):366-378.
Score: 0.147
-
Extensive Disease and Exposure to Multiple Biologics Precolectomy Is Associated with Endoscopic Cuffitis Post-Ileal Pouch-Anal Anastomosis in Patients With Ulcerative Colitis. Inflamm Bowel Dis. 2024 Mar 23.
Score: 0.060
-
Microbially-catalyzed conjugation of GABA and tyramine to bile acids. bioRxiv. 2023 Dec 13.
Score: 0.059
-
Multiomic analysis reveals cellular and epigenetic plasticity in intestinal pouches of ulcerative colitis patients. medRxiv. 2023 Nov 13.
Score: 0.058
-
Inflammation in the proximal colon is a risk factor for the development of colorectal neoplasia in inflammatory bowel disease patients with primary sclerosing cholangitis. Therap Adv Gastroenterol. 2023; 16:17562848231184985.
Score: 0.058
-
Serum Cytomegalovirus Polymerase Chain Reaction Test Is a Valuable Negative Predictor of Infection in Acute Severe Ulcerative Colitis. Dig Dis Sci. 2023 03; 68(3):897-901.
Score: 0.053
-
Vedolizumab for perianal fistulizing Crohn's disease: systematic review and meta-analysis. Intest Res. 2022 Apr; 20(2):240-250.
Score: 0.052
-
A Clinical Predictive Model for One-year Colectomy in Adults Hospitalized for Severe Ulcerative Colitis. Crohns Colitis 360. 2022 Jan; 4(1):otab082.
Score: 0.051
-
Inpatient Therapy With Calcineurin Inhibitors in Severe Ulcerative Colitis. Inflamm Bowel Dis. 2021 10 18; 27(10):1620-1625.
Score: 0.051
-
Predictability of simple endoscopic score for Crohn's disease for postoperative outcomes in Crohn's disease. J Gastroenterol Hepatol. 2021 Oct; 36(10):2785-2793.
Score: 0.049
-
The Correlation between Vitamin D Levels and the Risk of Postoperative Recurrence in Crohn's Disease. Digestion. 2021; 102(5):767-775.
Score: 0.048
-
Daily Aspirin Use Does Not Impact Clinical Outcomes in Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2021 01 19; 27(2):236-241.
Score: 0.048
-
Effective Treatment of Acute Severe Ulcerative Colitis in Pregnancy Is Associated With Good Maternal and Fetal Outcomes. Clin Gastroenterol Hepatol. 2021 11; 19(11):2444-2446.e2.
Score: 0.047
-
Low Skeletal Muscle Index Adjusted for Body Mass Index Is an Independent Risk Factor for Inflammatory Bowel Disease Surgical Complications. Crohns Colitis 360. 2020 Jul; 2(3):otaa064.
Score: 0.046
-
Efficacy of biosimilar infliximab CT-P13 among inpatients with severe steroid-refractory colitis. Int J Colorectal Dis. 2020 Nov; 35(11):2113-2116.
Score: 0.046
-
Risk factors and treatment outcomes of peristomal pyoderma gangrenosum in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2020 06; 51(12):1365-1372.
Score: 0.046
-
Effectiveness of Ustekinumab Dose Escalation in Patients With Crohn's Disease. Clin Gastroenterol Hepatol. 2021 01; 19(1):104-110.
Score: 0.045
-
Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission. J Gastroenterol Hepatol. 2019 Dec; 34(12):2090-2095.
Score: 0.043
-
Differential risk of disease progression between isolated anastomotic ulcers and mild ileal recurrence after ileocolonic resection in patients with Crohn's disease. Gastrointest Endosc. 2019 08; 90(2):269-275.
Score: 0.042
-
A comparison of the risk of postoperative recurrence between African-American and Caucasian patients with Crohn's disease. Aliment Pharmacol Ther. 2018 11; 48(9):933-940.
Score: 0.041
-
Rapid Onset of Inflammatory Bowel Disease after Receiving Secukinumab Infusion. ACG Case Rep J. 2018; 5:e56.
Score: 0.040
-
Clinical Response and Complications are not Associated with Drug Levels in Patients with Severe Ulcerative Colitis on IV Cyclosporine Induction Therapy. Inflamm Bowel Dis. 2018 05 18; 24(6):1291-1297.
Score: 0.040
-
The Use of Vedolizumab in Preventing Postoperative Recurrence of Crohn's Disease. Inflamm Bowel Dis. 2018 02 15; 24(3):502-509.
Score: 0.039
-
Risk of Postoperative Complications Among Inflammatory Bowel Disease Patients Treated Preoperatively With Vedolizumab. Am J Gastroenterol. 2017 Sep; 112(9):1423-1429.
Score: 0.038
-
Early Transcriptomic Changes in the Ileal Pouch Provide Insight into the Molecular Pathogenesis of Pouchitis and Ulcerative Colitis. Inflamm Bowel Dis. 2017 Feb 13.
Score: 0.037
-
Patient-Specific Bacteroides Genome Variants in Pouchitis. mBio. 2016 11 15; 7(6).
Score: 0.036
-
Insights into the pathogenesis of ulcerative colitis from a murine model of stasis-induced dysbiosis, colonic metaplasia, and genetic susceptibility. Am J Physiol Gastrointest Liver Physiol. 2016 06 01; 310(11):G973-88.
Score: 0.035